In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Malaria: Advances in Pathophysiology, Biology, and Drug Development

Edited by Edited by Annals of the New York Academy of Sciences editorial staff
Malaria: Advances in Pathophysiology, Biology, and Drug Development

Published: April 2015

Volume 1342

Learn More

Malaria remains a global health threat, putting an estimated 3.4 billion people at risk for infection. In 2012 alone, approximately 207 million people were diagnosed with malaria, ultimately resulting in 627,000 deaths, most of which occurred in Sub-Saharan Africa. This Annals volume presents a collection of papers stemming from the conference “Malaria 2014: Advances in Pathophysiology, Biology and Drug Development”, April 25, 2014, presented by the Microbiology & Infectious Diseases Discussion Group of the New York Academy of Sciences. The papers discuss recent research on the pathophysiology and biology of malaria and the development of antimalarial drugs, including the molecular basis of antifolate resistance in Plasmodium falciparum; translational regulation during stage transitions in malaria parasites; purine import into malaria parasites as a target for antimalarial drug development; the opportunities for, and challenges of, modeling malaria in humanized mice; the innate and adaptive response to mosquito saliva and Plasmodium sporozoites in the skin; the pathogenesis of pediatric cerebral malaria; the biology of Plasmodium vivax explored through genomics; and antimalarial drug resistance in Africa.